Eyenovia ROE 2016-2025 | HYPD
Current and historical return on equity (ROE) values for Eyenovia (HYPD) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Eyenovia ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2025-03-31 |
$-0.04B |
$-0.01B |
800.00% |
| 2024-12-31 |
$-0.05B |
$-0.01B |
2222.22% |
| 2024-09-30 |
$-0.04B |
$0.00B |
-1169.23% |
| 2024-06-30 |
$-0.04B |
$0.00B |
-592.00% |
| 2024-03-31 |
$-0.03B |
$0.00B |
-336.84% |
| 2023-12-31 |
$-0.03B |
$0.01B |
-207.69% |
| 2023-09-30 |
$-0.03B |
$0.02B |
-166.67% |
| 2023-06-30 |
$-0.03B |
$0.01B |
-156.25% |
| 2023-03-31 |
$-0.03B |
$0.02B |
-135.06% |
| 2022-12-31 |
$-0.03B |
$0.02B |
-118.68% |
| 2022-09-30 |
$-0.02B |
$0.02B |
-76.60% |
| 2022-06-30 |
$-0.02B |
$0.02B |
-87.18% |
| 2022-03-31 |
$-0.02B |
$0.03B |
-95.24% |
| 2021-12-31 |
$-0.01B |
$0.02B |
-115.56% |
| 2021-09-30 |
$-0.02B |
$0.00B |
-200.00% |
| 2021-06-30 |
$-0.02B |
$0.01B |
-138.18% |
| 2021-03-31 |
$-0.02B |
$0.01B |
-140.74% |
| 2020-12-31 |
$-0.02B |
$0.02B |
-140.74% |
| 2020-09-30 |
$-0.02B |
$0.02B |
-156.86% |
| 2020-06-30 |
$-0.02B |
$0.01B |
-166.67% |
| 2020-03-31 |
$-0.02B |
$0.01B |
-166.67% |
| 2019-12-31 |
$-0.02B |
$0.01B |
-175.00% |
| 2019-09-30 |
$-0.02B |
$0.02B |
-166.04% |
| 2019-06-30 |
$-0.02B |
$0.01B |
-147.37% |
| 2019-03-31 |
$-0.02B |
$0.01B |
-104.11% |
| 2018-12-31 |
$-0.02B |
$0.02B |
-72.73% |
| 2018-09-30 |
$-0.01B |
$0.02B |
-63.16% |
| 2018-06-30 |
$-0.01B |
$0.02B |
-63.16% |
| 2018-03-31 |
$-0.01B |
$0.03B |
-84.85% |
| 2017-12-31 |
$-0.01B |
$0.01B |
-333.33% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.041B |
$0.000B |
|
Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York.
|
